Loading...
XNAS
VCEL
Market cap2.02bUSD
Jul 25, Last price  
40.12USD
1D
1.01%
1Q
0.98%
Jan 2017
1,237.33%
Name

Vericel Corp

Chart & Performance

D1W1MN
P/E
194.92
P/S
8.51
EPS
0.21
Div Yield, %
—
Shrs. gr., 5y
3.19%
Rev. gr., 5y
15.02%
Revenues
237m
+20.10%
909,000863,000685,000522,000182,00089,00018,00021,00019,00028,796,00051,168,00054,383,00063,924,00090,857,000117,850,000124,179,000156,184,000164,365,000197,516,000237,224,000
Net income
10m
P
-11,811,000-16,475,000-17,594,000-20,133,000-15,946,000-17,729,000-19,668,000-29,474,000-15,622,000-19,920,000-16,340,000-19,566,000-17,286,000-8,137,000-7,909,0002,864,000-7,471,000-16,709,000-3,182,00010,362,000
CFO
58m
+64.72%
-11,065,000-13,518,000-14,826,000-19,527,000-13,805,000-15,085,000-24,492,000-29,545,000-19,943,000-25,410,000-13,346,000-19,892,000-13,183,000-412,000-7,183,00017,572,00029,040,00017,687,00035,311,00058,163,000
Earnings
Jul 30, 2025

Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
URL
https://vcel.com/
IPO date
Feb 04, 1997
Employees
305
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
237,224
20.10%
197,516
20.17%
164,365
5.24%
Cost of revenue
89,914
82,982
74,520
Unusual Expense (Income)
NOPBT
147,310
114,534
89,845
NOPBT Margin
62.10%
57.99%
54.66%
Operating Taxes
148
814
721
Tax Rate
0.10%
0.71%
0.80%
NOPAT
147,162
113,720
89,124
Net income
10,362
-425.64%
(3,182)
-80.96%
(16,709)
123.65%
Dividends
Dividend yield
Proceeds from repurchase of equity
24,516
6,000
3,652
BB yield
-0.86%
-0.35%
-0.29%
Debt
Debt current
9,257
12,374
4,302
Long-term debt
188,443
169,899
90,838
Deferred revenue
Other long-term liabilities
876
100
Net debt
41,607
47,433
(44,360)
Cash flow
Cash from operating activities
58,163
35,311
17,687
CAPEX
(7,596)
Cash from investing activities
(79,034)
(3,130)
(36,206)
Cash from financing activities
19,054
3,618
1,045
FCF
96,164
27,463
88,575
Balance
Cash
116,213
109,557
119,538
Long term investments
39,880
25,283
19,962
Excess cash
144,232
124,964
131,282
Stockholders' equity
291,967
225,952
192,272
Invested Capital
247,461
195,318
108,560
ROIC
66.47%
74.85%
85.74%
ROCE
37.61%
35.76%
37.46%
EV
Common stock shares outstanding
51,679
47,590
47,130
Price
54.91
54.20%
35.61
35.19%
26.34
-32.98%
Market cap
2,837,694
67.45%
1,694,680
36.51%
1,241,404
-32.03%
EV
2,879,301
1,742,113
1,197,044
EBITDA
152,157
119,166
93,826
EV/EBITDA
18.92
14.62
12.76
Interest
614
600
366
Interest/NOPBT
0.42%
0.52%
0.41%